Literature DB >> 10506287

Design, engineering and production of functional single-chain T cell receptor ligands.

G G Burrows1, J W Chang, H P Bächinger, D N Bourdette, H Offner, A A Vandenbark.   

Abstract

Major histocompatibility complex (MHC) class II molecules are membrane-anchored heterodimers on the surface of antigen presenting cells (APCs) that bind the T cell receptor, initiating a cascade of interactions that results in antigen-specific activation of clonal populations of T cells. The peptide binding/T cell recognition domains of rat MHC class II (alpha-1 and beta-1 domains) were expressed as a single exon for structural and functional characterization. These recombinant single-chain T cell receptor ligands (termed 'beta1alpha1' molecules) of approximately 200 amino acid residues were designed using the structural backbone of MHC class II molecules as template, and have been produced in Escherichia coli with and without N-terminal extensions containing antigenic peptides. Structural characterization using circular dichroism predicted that these molecules retained the antiparallel beta-sheet platform and antiparallel alpha-helices observed in the native MHC class II heterodimer. The proteins exhibited a cooperative two-state thermal folding-unfolding transition. Beta1alpha1 molecules with a covalently linked MBP-72-89 peptide showed increased stability to thermal unfolding relative to the empty beta1alpha1 molecules. This new class of small soluble polypeptide provides a template for designing and refining human homologues useful in detecting and regulating pathogenic T cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10506287     DOI: 10.1093/protein/12.9.771

Source DB:  PubMed          Journal:  Protein Eng        ISSN: 0269-2139


  37 in total

1.  Neuroprotective effects of recombinant T-cell receptor ligand in autoimmune optic neuritis in HLA-DR2 mice.

Authors:  Grazyna Adamus; Lori Brown; Shayne Andrew; Roberto Meza-Romero; Gregory G Burrows; Arthur A Vandenbark
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-01-25       Impact factor: 4.799

Review 2.  Systemic immunomodulation of autoimmune disease using MHC-derived recombinant TCR ligands.

Authors:  Gregory G Burrows
Journal:  Curr Drug Targets Inflamm Allergy       Date:  2005-04

Review 3.  Peptide-MHC-based nanovaccines for the treatment of autoimmunity: a "one size fits all" approach?

Authors:  Xavier Clemente-Casares; Sue Tsai; Yang Yang; Pere Santamaria
Journal:  J Mol Med (Berl)       Date:  2011-04-16       Impact factor: 4.599

Review 4.  Class II major histocompatibility complex tetramer staining: progress, problems, and prospects.

Authors:  Sabrina S Vollers; Lawrence J Stern
Journal:  Immunology       Date:  2008-03       Impact factor: 7.397

Review 5.  Recombinant T cell receptor ligands: immunomodulatory, neuroprotective and neuroregenerative effects suggest application as therapy for multiple sclerosis.

Authors:  Halina Offner; Sushmita Sinha; Chunhe Wang; Gregory G Burrows; Arthur A Vandenbark
Journal:  Rev Neurosci       Date:  2008       Impact factor: 4.353

6.  Recombinant T cell receptor ligand treatment improves neurological outcome in the presence of tissue plasminogen activator in experimental ischemic stroke.

Authors:  Wenbin Zhu; Nicole L Libal; Amanda Casper; Sheetal Bodhankar; Halina Offner; Nabil J Alkayed
Journal:  Transl Stroke Res       Date:  2014-06-24       Impact factor: 6.829

7.  A novel HLA-DRα1-MOG-35-55 construct treats experimental stroke.

Authors:  Gil Benedek; Wenbin Zhu; Nicole Libal; Amanda Casper; Xiaolin Yu; Roberto Meza-Romero; Arthur A Vandenbark; Nabil J Alkayed; Halina Offner
Journal:  Metab Brain Dis       Date:  2014-03       Impact factor: 3.584

8.  Rationally designed mutations convert complexes of human recombinant T cell receptor ligands into monomers that retain biological activity.

Authors:  Jianya Y Huan; Roberto Meza-Romero; Jeffery L Mooney; Yuan K Chou; David M Edwards; Cathleen Rich; Jason M Link; Arthur A Vandenbark; Dennis N Bourdette; Hans-Peter Bächinger; Gregory G Burrows
Journal:  J Chem Technol Biotechnol       Date:  2004-10-12       Impact factor: 3.174

9.  Recombinant T cell receptor ligand treats experimental stroke.

Authors:  Sandhya Subramanian; Bing Zhang; Yasuharu Kosaka; Gregory G Burrows; Marjorie R Grafe; Arthur A Vandenbark; Patricia D Hurn; Halina Offner
Journal:  Stroke       Date:  2009-05-14       Impact factor: 7.914

10.  Characterization of human platelet binding of recombinant T cell receptor ligand.

Authors:  Asako Itakura; Joseph E Aslan; Sushmita Sinha; Tara C White-Adams; Ishan A Patel; Roberto Meza-Romero; Arthur A Vandenbark; Gregory G Burrows; Halina Offner; Owen Jt McCarty
Journal:  J Neuroinflammation       Date:  2010-11-08       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.